166 related articles for article (PubMed ID: 33284384)
1. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.
Donohue JF; Burgoyne DS; Ward JK; Allan R; Koltun A; Cooper A
Pulm Ther; 2021 Jun; 7(1):47-57. PubMed ID: 33284384
[TBL] [Abstract][Full Text] [Related]
2. Wixela Inhub: Dosing Performance
Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
[No Abstract] [Full Text] [Related]
3. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Ng D; Kerwin EM; White MV; Miller SD; Haughie S; Ward JK; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):99-107. PubMed ID: 31634023
[No Abstract] [Full Text] [Related]
4. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
Tashkin DP; Ohar JA; Koltun A; Allan R; Ward JK
Pulm Med; 2021; 2021():8881895. PubMed ID: 33815843
[TBL] [Abstract][Full Text] [Related]
5. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
Haughie S; Allan R; Wood N; Ward J
J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
[No Abstract] [Full Text] [Related]
6.
Shepherd T; Kennett M; Cooper A; Parkinson A
J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
[No Abstract] [Full Text] [Related]
7. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
Allan R; Canham K; Wallace R; Singh D; Ward J; Cooper A; Newcomb C
J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
[No Abstract] [Full Text] [Related]
8. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB; Kesselheim AS; Avorn J; Russo M; Wang SV
Ann Intern Med; 2023 Aug; 176(8):1047-1056. PubMed ID: 37549393
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
10. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
Fenton C; Keating GM
Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
[TBL] [Abstract][Full Text] [Related]
11. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
12. Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma.
Longphre MV; Getz EB; Fuller R
Ann Am Thorac Soc; 2017 Feb; 14(2):182-189. PubMed ID: 27849125
[TBL] [Abstract][Full Text] [Related]
13. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma.
Reynolds NA; Lyseng-Williamson KA; Wiseman LR
Drugs; 2005; 65(12):1715-34. PubMed ID: 16060707
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
[TBL] [Abstract][Full Text] [Related]
17. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.
Chan R; Sousa AR; Hynds P; Homayoun-Valiani F; Edwards D; Tabberer M
Pulm Pharmacol Ther; 2017 Apr; 43():12-19. PubMed ID: 28115223
[TBL] [Abstract][Full Text] [Related]
19. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.
Aubier M; Pieters WR; Schlösser NJ; Steinmetz KO
Respir Med; 1999 Dec; 93(12):876-84. PubMed ID: 10653049
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
